1区 · 综合性期刊
ArticleOA
作者: Vedadi, Masoud ; Ivanochko, Danton ; Lima-Fernandes, Evelyne ; Brown, Peter J ; Szewczyk, Magdalena M ; Bok, Jabez ; Bennett, D Jonathan ; Schapira, Matthieu ; Ho, Jessica Sook Yuin ; Luciani, Genna M ; Guccione, Ernesto ; Kaldis, Philipp ; Wu, Qin ; Li, Fengling ; Gay, Florence P H ; Blazer, Levi ; Dilworth, David ; Barsyte-Lovejoy, Dalia ; Halabelian, Levon ; Kattar, Solomon D ; O'Hagan, Ronan C ; Sanders, John M ; Arrowsmith, Cheryl H ; Allali-Hassani, Abdellah ; Palmer, Nathan ; Nicholson, Benjamin ; Talib, S Zakiah A ; Organ, Shawna L ; Loppnau, Peter ; Eram, Mohammad S
Abstract:PRDM9 is a PR domain containing protein which trimethylates histone 3 on lysine 4 and 36. Its normal expression is restricted to germ cells and attenuation of its activity results in altered meiotic gene transcription, impairment of double-stranded breaks and pairing between homologous chromosomes. There is growing evidence for a role of aberrant expression of PRDM9 in oncogenesis and genome instability. Here we report the discovery of MRK-740, a potent (IC50: 80 ± 16 nM), selective and cell-active PRDM9 inhibitor (Chemical Probe). MRK-740 binds in the substrate-binding pocket, with unusually extensive interactions with the cofactor S-adenosylmethionine (SAM), conferring SAM-dependent substrate-competitive inhibition. In cells, MRK-740 specifically and directly inhibits H3K4 methylation at endogenous PRDM9 target loci, whereas the closely related inactive control compound, MRK-740-NC, does not. The discovery of MRK-740 as a chemical probe for the PRDM subfamily of methyltransferases highlights the potential for exploiting SAM in targeting SAM-dependent methyltransferases.